Recent studies have converged on the overlap of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopamine communication. While GCGR agonists are increasingly employed for addressing type 2 T2DM, their unexpected consequences on reinforcement circuits, specifically mediated by dopamine… Read More